skip to main content
OSTI.GOV title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: Boron-containing nucleosides for neutron capture therapy

Conference · · Trans. Am. Nucl. Soc.; (United States)
OSTI ID:6718122

There is widespread and increasing interest in the preparation of organoboron compounds for their potential medical application for neutron capture therapy (NCT). The authors approach was to synthesize a boron-containing pyrimidine nucleoside,5-dihydroxyboryl-2'-deoxyuridine (DBDU), which could act as a sensitizing agent in boron neutron-capture reactions. Irradiation of tumor cells that have incorporated boron nucleoside with neutrons would, therefore, principally destroy only tumor tissue. Since the nucleoside would be localized primarily in the nucleus, the greater biological efficacy would permit utilization of lower boron concentrations. Synthetic procedures to novel boron nucleosides and pyrimidines that could be of potential utility for NCT have been worked out. These include the synthesis of 2-thio-5-dihydroxyboryluracil and 2,4-dithio-5-dihydroxyboryluracil, which may be taken up selectively in melanoma cells as analogues of 2-thiouracil; and 6-dihydroxyborylpurine-2'-deoxyriboside, an analogue of 2'-deoxyadenosine. Studies with these compounds will allow the authors to determine the potential use of these boron nucleosides and pyrimidines for boron NCT, with the aim of reducing mortality and increasing life span of patients with diagnosed gliomas, melanomas and other tumors.

Research Organization:
VA Medical Center, Atlanta, GA
OSTI ID:
6718122
Report Number(s):
CONF-861102-
Journal Information:
Trans. Am. Nucl. Soc.; (United States), Vol. 53; Conference: American Nuclear Society and Atomic Industrial Forum joint meeting, Washington, DC, USA, 16 Nov 1986
Country of Publication:
United States
Language:
English